American Association for Cancer Research (AACR) annual meeting 2014, 
      abstract 831; Cancer Research 2014, 74 (19 supplement) 
 
  12. A. Schmitt-Hoffmann, D. Klauer, K. Gebhardt et al. BAL27862: a unique 
      microtubule-targeted agent with a potential for the treatment of human 
      brain tumors. AACR-NCI-EORTC conference 2009, abstract C233; Molecular 
      Cancer Therapeutics 2009, 8 (12 supplement) 
 
  13. A. C. Mladek, J. L. Pokorny, H. Lane et al. The novel tubulin-binding 
      'tumor checkpoint controller' BAL101553 has anti-cancer activity alone 
      and in combination treatments across a panel of GBM patient-derived 
      xenografts. American Association for Cancer Research (AACR) annual 
      meeting 2016, abstract 4781; Cancer Research 2016, 76 (14 supplement) 
 
  14. A. E. Prota, F. Danel, F. Bachmann et al. The novel 
      microtubule-destabilizing drug BAL27862 binds to the colchicine site of 
      tubulin with distinct effects on microtubule organization. Journal of 
      Molecular Biology 2014 (426), 1848-1860 
 
  15. F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the 
      spindle assembly checkpoint is required for anticancer activity. American 
      Association for Cancer Research (AACR) annual meeting 2015, abstract 
      3789; Cancer Research 2015, 75 (15 supplement) 
 
 
   Attachment 
 
 
   -- Press release (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/3d59bbce-df2e-4ee6-89cb-e63c96206706

(END) Dow Jones Newswires

June 07, 2021 01:15 ET (05:15 GMT)